• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增强微环境内的相互作用加速了 TACE 后 HBV 相关 HCC 的预后不良。

Enhanced interactions within microenvironment accelerates dismal prognosis in HBV-related HCC after TACE.

机构信息

Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.

Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

出版信息

Hepatol Commun. 2024 Oct 3;8(10). doi: 10.1097/HC9.0000000000000548. eCollection 2024 Oct 1.

DOI:10.1097/HC9.0000000000000548
PMID:39365124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11458170/
Abstract

BACKGROUND

Transarterial chemoembolization (TACE) is the first-line treatment for patients with advanced HCC, but there are limited studies on the microenvironment alterations caused by TACE.

METHODS

Six fresh HBV-related HCC specimens with or without TACE intervention were used to perform single-cell RNA sequencing. The 757 bulk samples from 3 large-scale multicenter cohorts were applied for comprehensive analysis. The biological functions of the biomarkers were further validated by phenotypic experiments.

RESULTS

Using single-cell RNA sequencing analysis, we delineated the global cell atlas of post-TACE and demonstrated elevated tumor heterogeneity and an enhanced proinflammatory microenvironment induced by TACE. Cell-cell communication analysis revealed that markedly elevated interactions between NABP1+ malignant hepatocytes, neutrophils, and CD8+ T cells after TACE might accelerate the shift from CD8+ effector memory T cells to CD8+ effector T cells. This result was substantiated by the developmental trajectory between the 2 and dramatically decreased resident scores along the pseudotemporal trajectory. Integrating bulk data, we further found that the increased estimated proportion of NABP1+ malignant hepatocytes was related to poor TACE response and dismal prognosis, and its biomarker role could be replaced by NABP1. In vitro, multiple biological experiments consistently verified that NABP1 knockdown significantly inhibited the proliferation and migration of HCC cells.

CONCLUSIONS

Based on our depicted global map of post-TACE, we confirmed that the enhanced interactions within the microenvironment after TACE may be the culprits for postoperative progression. NABP1 may become an attractive tool for the early identification of patients sensitive to first-line TACE in clinical practice.

摘要

背景

经动脉化疗栓塞术(TACE)是治疗晚期 HCC 患者的一线治疗方法,但关于 TACE 引起的微环境改变的研究有限。

方法

使用单细胞 RNA 测序分析对 6 例伴有或不伴有 TACE 干预的 HBV 相关 HCC 新鲜标本进行分析。对 3 个大型多中心队列的 757 个批量样本进行综合分析。通过表型实验进一步验证了生物标志物的生物学功能。

结果

通过单细胞 RNA 测序分析,我们描绘了 TACE 后的全局细胞图谱,并证明 TACE 引起的肿瘤异质性和促炎微环境增强。细胞间通讯分析表明,TACE 后 NABP1+恶性肝细胞、中性粒细胞和 CD8+T 细胞之间的相互作用明显增加,可能加速 CD8+效应记忆 T 细胞向 CD8+效应 T 细胞的转变。这一结果通过 2 个之间的发育轨迹以及伪时间轨迹上的驻留评分明显降低得到证实。整合批量数据,我们进一步发现,NABP1+恶性肝细胞的估计比例增加与 TACE 反应不良和预后不良有关,其生物标志物作用可被 NABP1 取代。在体外,多项生物学实验一致证实,NABP1 敲低显著抑制 HCC 细胞的增殖和迁移。

结论

基于我们描绘的 TACE 后全局图谱,我们证实 TACE 后微环境内增强的相互作用可能是术后进展的罪魁祸首。NABP1 可能成为临床实践中识别对一线 TACE 敏感患者的有吸引力的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/2112726e77bb/hc9-8-e0548-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/774385a57619/hc9-8-e0548-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/219ebf7cfc6f/hc9-8-e0548-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/926558f8ccd8/hc9-8-e0548-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/03638e2c8470/hc9-8-e0548-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/0cad2688515d/hc9-8-e0548-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/2112726e77bb/hc9-8-e0548-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/774385a57619/hc9-8-e0548-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/219ebf7cfc6f/hc9-8-e0548-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/926558f8ccd8/hc9-8-e0548-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/03638e2c8470/hc9-8-e0548-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/0cad2688515d/hc9-8-e0548-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538f/11458170/2112726e77bb/hc9-8-e0548-g006.jpg

相似文献

1
Enhanced interactions within microenvironment accelerates dismal prognosis in HBV-related HCC after TACE.增强微环境内的相互作用加速了 TACE 后 HBV 相关 HCC 的预后不良。
Hepatol Commun. 2024 Oct 3;8(10). doi: 10.1097/HC9.0000000000000548. eCollection 2024 Oct 1.
2
Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.回顾性分析肝细胞癌经动脉区域性局部治疗的免疫效应:选择性内放射治疗(SIRT)联合免疫治疗的原理。
BMC Cancer. 2020 Feb 19;20(1):135. doi: 10.1186/s12885-020-6613-1.
3
TREM2 macrophages suppress CD8 T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma.TREM2 巨噬细胞抑制肝癌经动脉化疗栓塞术后 CD8+T 细胞浸润。
J Hepatol. 2023 Jul;79(1):126-140. doi: 10.1016/j.jhep.2023.02.032. Epub 2023 Mar 6.
4
Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative.经动脉化疗栓塞联合抗病毒治疗对HBV-DNA阴性的HBV相关肝细胞癌患者HBV再激活及肝功能的影响
Medicine (Baltimore). 2018 Jun;97(22):e10940. doi: 10.1097/MD.0000000000010940.
5
Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles.经微球动脉化疗栓塞术治疗后肝癌患者外周血 Treg 细胞比例的变化。
Front Immunol. 2021 Feb 24;12:624789. doi: 10.3389/fimmu.2021.624789. eCollection 2021.
6
Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis.经导管动脉化疗栓塞术(TACE)和预防性抗病毒治疗对肝细胞癌(HCC)HBV 再激活及随后肝炎的影响:一项荟萃分析。
Jpn J Clin Oncol. 2019 Jul 1;49(7):646-655. doi: 10.1093/jjco/hyz046.
7
Postsurgical treatment with adjuvant transarterial chemoembolization in patients with hepatitis B-related hepatocellular carcinoma: A strobe-compliant article.乙肝相关肝细胞癌患者术后辅助经动脉化疗栓塞治疗:一篇符合STROBE标准的文章。
Medicine (Baltimore). 2016 Dec;95(52):e5517. doi: 10.1097/MD.0000000000005517.
8
Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.SLC1A5 水平升高与肝细胞癌经动脉化疗栓塞治疗预后不良和耐药相关。
J Transl Med. 2024 Jun 6;22(1):543. doi: 10.1186/s12967-024-05298-1.
9
Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma.TP53突变对乙肝相关晚期肝细胞癌经动脉化疗栓塞术失败/难治性的预后价值
Cancer Res Treat. 2020 Jul;52(3):925-937. doi: 10.4143/crt.2019.533. Epub 2020 Mar 30.
10
Prognostic and therapeutic potential of imbalance between PD-1+CD8 and ICOS+Treg cells in advanced HBV-HCC.PD-1+CD8 与 ICOS+Treg 细胞失衡对晚期 HBV-HCC 的预后和治疗潜力。
Cancer Sci. 2024 Aug;115(8):2553-2564. doi: 10.1111/cas.16247. Epub 2024 Jun 15.

引用本文的文献

1
Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC.肿瘤微环境与肝癌经动脉及全身治疗耐药性之间的相互作用。
Cancer Drug Resist. 2025 Jul 2;8:33. doi: 10.20517/cdr.2024.212. eCollection 2025.

本文引用的文献

1
Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy.针对 IGF2 重编程肿瘤微环境以增强病毒免疫治疗。
Neuro Oncol. 2024 Sep 5;26(9):1602-1616. doi: 10.1093/neuonc/noae105.
2
The role of CXCL family members in different diseases.CXCL家族成员在不同疾病中的作用。
Cell Death Discov. 2023 Jul 1;9(1):212. doi: 10.1038/s41420-023-01524-9.
3
A neutrophil response linked to tumor control in immunotherapy.免疫治疗中与肿瘤控制相关的中性粒细胞反应。
Cell. 2023 Mar 30;186(7):1448-1464.e20. doi: 10.1016/j.cell.2023.02.032.
4
TREM2 macrophages suppress CD8 T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma.TREM2 巨噬细胞抑制肝癌经动脉化疗栓塞术后 CD8+T 细胞浸润。
J Hepatol. 2023 Jul;79(1):126-140. doi: 10.1016/j.jhep.2023.02.032. Epub 2023 Mar 6.
5
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.在肝癌微环境中鉴定决定免疫治疗疗效的肿瘤免疫屏障。
J Hepatol. 2023 Apr;78(4):770-782. doi: 10.1016/j.jhep.2023.01.011. Epub 2023 Jan 26.
6
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
7
Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences.独特的单细胞免疫生态系统可区分真正的和新出现的 HBV 相关肝细胞癌复发。
Gut. 2023 Jun;72(6):1196-1210. doi: 10.1136/gutjnl-2022-328428. Epub 2023 Jan 3.
8
Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment.奥沙利铂耐药肝细胞癌通过 PD-L1 上调和PMN 募集驱动免疫逃逸。
Cell Mol Gastroenterol Hepatol. 2023;15(3):573-591. doi: 10.1016/j.jcmgh.2022.12.002. Epub 2022 Dec 10.
9
Liver tumour immune microenvironment subtypes and neutrophil heterogeneity.肝肿瘤免疫微环境亚型与中性粒细胞异质性
Nature. 2022 Dec;612(7938):141-147. doi: 10.1038/s41586-022-05400-x. Epub 2022 Nov 9.
10
S100A9 Derived from Chemoembolization-Induced Hypoxia Governs Mitochondrial Function in Hepatocellular Carcinoma Progression.S100A9 来源于化疗栓塞诱导的缺氧,可调控肝癌进展中的线粒体功能。
Adv Sci (Weinh). 2022 Oct;9(30):e2202206. doi: 10.1002/advs.202202206. Epub 2022 Aug 30.